vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $13.7M, roughly 1.0× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -342.3%, a 418.0% gap on every dollar of revenue.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
GOSS vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $13.7M |
| Net Profit | $-47.2M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -333.6% | -86.5% |
| Net Margin | -342.3% | 75.7% |
| Revenue YoY | 47.1% | — |
| Net Profit YoY | -43.0% | 179.1% |
| EPS (diluted) | $-0.21 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $13.7M | ||
| Q3 25 | $13.3M | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q2 24 | $95.8M | — | ||
| Q1 24 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q4 25 | $-47.2M | $10.4M | ||
| Q3 25 | $-48.2M | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-13.3M | ||
| Q2 24 | $49.2M | — | ||
| Q1 24 | $-41.9M | — | ||
| Q3 23 | $-40.0M | — | ||
| Q2 23 | $-42.5M | — |
| Q4 25 | -333.6% | -86.5% | ||
| Q3 25 | -369.4% | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q2 24 | 54.3% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -342.3% | 75.7% | ||
| Q3 25 | -362.7% | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | — | -452.7% | ||
| Q2 24 | 51.4% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $-0.21 | $-3.74 | ||
| Q3 25 | $-0.21 | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q2 24 | $0.22 | — | ||
| Q1 24 | $-0.19 | — | ||
| Q3 23 | $-0.21 | — | ||
| Q2 23 | $-0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $35.3M |
| Total Assets | $172.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | $137.5M | ||
| Q3 25 | $180.2M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q2 24 | $354.5M | — | ||
| Q1 24 | $244.4M | — | ||
| Q3 23 | $328.9M | — | ||
| Q2 23 | $162.1M | — |
| Q4 25 | $-122.8M | $35.3M | ||
| Q3 25 | $-82.3M | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $10.7M | ||
| Q2 24 | $81.5M | — | ||
| Q1 24 | $26.7M | — | ||
| Q3 23 | $104.6M | — | ||
| Q2 23 | $-62.8M | — |
| Q4 25 | $172.2M | $154.7M | ||
| Q3 25 | $208.8M | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | — | $103.7M | ||
| Q2 24 | $373.4M | — | ||
| Q1 24 | $259.4M | — | ||
| Q3 23 | $347.9M | — | ||
| Q2 23 | $181.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $-2.0M | ||
| Q3 25 | $-36.2M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M | ||
| Q2 24 | $116.3M | — | ||
| Q1 24 | $-52.3M | — | ||
| Q3 23 | $-34.5M | — | ||
| Q2 23 | $-38.3M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
